Showing all news

MRC Technology joins project UTILE to enable medical breakthroughs from European funded research

MRC Technology is committed to ensuring that promising medical research is protected and progressed to benefit patients. We are therefore pleased to announce that we are funding partners in an international technology transfer consortium set up to enable translation of health research into new diagnostics and medicines. The UTILE Project will facilitate partnering and licensing opportunities for research funded under the Seventh Framework Programme (FP7) Health and Societal Challenge 1 of Horizon 2020.

UTILE, a Horizon 2020 funded project, will develop an online marketplace to bring together innovation providers and innovation developers, combining technology push and market pull approaches. It aims to add value to promising research to maximise results. UTILE will also provide recommendations to the European Commission for future research and technology transfer within the health sector.

The international consortium is led by PNO Consultants BV (NL) and includes technology transfer organisations: Ascenion GmbH (DE); ASTP Proton (NL); Bergen Teknologioverforing AS (BTO) (NO); Karolinska Institutet Innovations AB (SE); MRC Technology (UK); Tech Transfer Summit Ltd. (UK); and commercial organisations: Ciaotech Srl (IT); Europroject Ood (BG); Europe Unlimited SA (BE); and Innovation Engineering Srl (IT). The US National Institute of Health (NIH) is also actively involved in the project.

24 February 2017

Putting patient wellbeing and collaboration at the heart of what we do

  by Mike Johnson (First appeared on AMRC website, 21 November 2016) Which treatment or diagnostic would make a patient’s life better? This is the starting point of what MRC Technology does. Like other medical research charities, we exist to improve patients’ lives, but unlike them, we don’t focus on a specific disease but work across a range of diseases. Many charities are doing tremendous work to support patients and fund research into potential treatments. If we work together, we can create a much bigger wave towards positive… Read More

22 November 2016

Rethinking drug research, before it’s too late

Dr David Pardoe, Head of Growth Projects at MRC Technology (First appeared as part of MediaPlanet’s antibiotic resistance campaign) Antibiotic resistance As we face the prospect of living in a ‘post-antibiotic’ era, there is renewed urgency to rethink the way we approach both the research and the funding of drug innovation. When it comes to developing new drugs we typically build on the research we’ve done in the past. But in fighting gram-negative bacteria we’ve already tested everything that is likely to work, so we need a new approach.With… Read More

18 November 2016
Showing all news